From: The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients
Subgroup
MACOP-B
Rituximab
Radiotherapy
n(%)
1
Yes
No
11 (11.2%)
2
20 (20.4%)
3
37 (37.8%)
4
30 (30.6%)
Total (%)
98 (100%)
57 (58.2%)
67 (68.4%)